telmisartan has been researched along with favipiravir in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anglaret, X; Binquet, C; Bouchet, S; Crémer, A; Darnaud, T; Dupouy, J; Duvignaud, A; Gimbert, A; Joseph, JP; Journot, V; Lebeaux, D; Lebel, J; Lefèvre, B; Lhomme, E; Malvy, D; Michel, JF; Nguyen, D; Onaisi, R; Orne-Gliemann, J; Peiffer-Smadja, N; Piroth, L; Pistone, T; Poitrenaud, D; Richert, L; Roussillon, C; Sitta, R; Thiébaut, R; Wittkop, L | 1 |
1 trial(s) available for telmisartan and favipiravir
| Article | Year |
|---|---|
Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to R
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Antimalarials; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Drug Tolerance; Feasibility Studies; France; Hospitalization; Humans; Hydroxychloroquine; Imatinib Mesylate; Luxembourg; Outpatients; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrazines; Risk Reduction Behavior; SARS-CoV-2; Telmisartan; Therapies, Investigational; Treatment Outcome | 2020 |